Abstract:Introduction Thrombocytopaenia is one of the most common haemostatic abnormalities among neonates. It affects approximately one-quarter of neonates admitted into neonatal intensive care units and may lead to a high risk of bleeding and mortality, which are substantial causes for concern by neonatologists. Platelet transfusion (PT) is a specific treatment for thrombocytopaenia. To date, PT thresholds are diverse since the associations between low platelet count and negative outcomes are not clear. We propose this protocol for a systematic review to collect and assess evidence concerning the best PT threshold to reduce mortality, bleeding and major morbidity among neonates with thrombocytopaenia. Methods and analysis The systematic review will be performed according to the Cochrane Handbook for Systematic Review of Interventions, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, and the Grading of Recommendations Assessment, Development and Evaluation system. Two independent researchers will perform the study selection, data extraction/coding, quality assessment and further analyses of the included studies, with disagreements being resolved by a third researcher. A systematic search of the literature will be conducted in the PubMed, Cochrane Library and Embase databases from database inception through 13 October 2020. All randomised controlled trials, cohort studies and case–control studies will be included without any restrictions regarding publication date or language. The primary outcomes will comprise in-hospital mortality and bleeding episodes. Endnote X9 and Review Manager V.5.3 software will be used to manage the selection process and statistical analysis, respectively. If the included studies are sufficient and homogeneous for any of the outcomes, a quantitative synthesis (meta-analysis) may be performed. Otherwise, we will conduct a narrative systematic review of the results. Ethics and dissemination Ethical approval is not required for this study because the data will be obtained from published studies and will not include individual patient data. The results of this study are anticipated to be published in a peer-reviewed journal. PROSPERO registration number CRD42020169262.

Platelet function testing in pediatric patients

Platelet function tests: a comparative review

Analysis of platelet function and dysfunction

Flow cytometry for pediatric platelets

Platelet Function Testing: Update and Future Directions

Assessment of platelet function in the laboratory

Platelet Phenotyping and Function Testing in Thrombocytopenia

Diagnosis of Platelet Function Disorders: A Challenge for Laboratories

Platelet function testing: Update on determinant variables and permissive windows using a platelet-count-based device

Platelets from children are hyper-responsive to activation by thrombin receptor activator peptide and adenosine diphosphate compared to platelets from adults

Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond

Platelet Function Tests: A Review of Progresses in Clinical Application

Platelets in pediatric and neonatal sepsis: novel mediators of the inflammatory cascade

50 Years of Pediatric Hemostasis: Knowledge, Diagnosis, and Treatment

Congenital platelet disorders and understanding of platelet function

Toward Flow Cytometry Based Platelet Function Diagnostics

Antiplatelet Therapy in Pediatric Cardiovascular Patients

Methods for the Measurement of Platelet Function

Platelet transfusion for neonates with thrombocytopaenia: protocol for a systematic review

Development Of A High-Throughput Elisa Assay For Platelet Function Testing Using Platelet-Rich Plasma Or Whole Blood

Perioperative considerations in the paediatric patient with congenital and acquired coagulopathy